MDT

96.37

-0.07%↓

A

146.96

-0.22%↓

VEEV

227.95

-2.72%↓

HQY

83.09

-2.2%↓

PHR.US

16.49

-3.34%↓

MDT

96.37

-0.07%↓

A

146.96

-0.22%↓

VEEV

227.95

-2.72%↓

HQY

83.09

-2.2%↓

PHR.US

16.49

-3.34%↓

MDT

96.37

-0.07%↓

A

146.96

-0.22%↓

VEEV

227.95

-2.72%↓

HQY

83.09

-2.2%↓

PHR.US

16.49

-3.34%↓

MDT

96.37

-0.07%↓

A

146.96

-0.22%↓

VEEV

227.95

-2.72%↓

HQY

83.09

-2.2%↓

PHR.US

16.49

-3.34%↓

MDT

96.37

-0.07%↓

A

146.96

-0.22%↓

VEEV

227.95

-2.72%↓

HQY

83.09

-2.2%↓

PHR.US

16.49

-3.34%↓

Search

ResMed Inc

Abrir

SetorSaúde

255.16 -0.56

Visão Geral

Variação de preço das ações

24h

Atual

Mín

251.55

Máximo

262.31

Indicadores-chave

By Trading Economics

Rendimento

-31M

349M

Vendas

-12M

1.3B

P/E

Médio do Setor

25.114

87.826

Rendimento de Dividendos

0.89

Margem de lucro

26.096

Funcionários

10,600

EBITDA

-29M

503M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+14.02% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.89%

2.26%

Próximos Ganhos

29 de jan. de 2026

Próxima data de dividendos

19 de mar. de 2026

Próxima data de ex-dividendo

12 de fev. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-2B

36B

Abertura anterior

255.72

Fecho anterior

255.16

Sentimento de Notícias

By Acuity

34%

66%

109 / 370 Ranking em Healthcare

ResMed Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

12 de jan. de 2026, 23:54 UTC

Conversa de Mercado

CBA Could Underperform Again in 2026 -- Market Talk

12 de jan. de 2026, 23:48 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

12 de jan. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Rise on Weaker Yen -- Market Talk

12 de jan. de 2026, 23:43 UTC

Conversa de Mercado

Gold Edges Lower on Likely Technical Correction -- Market Talk

12 de jan. de 2026, 23:18 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12 de jan. de 2026, 21:56 UTC

Conversa de Mercado

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12 de jan. de 2026, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

12 de jan. de 2026, 21:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

12 de jan. de 2026, 21:50 UTC

Conversa de Mercado
Ganhos

Auto & Transport Roundup: Market Talk

12 de jan. de 2026, 21:18 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

12 de jan. de 2026, 21:18 UTC

Conversa de Mercado

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12 de jan. de 2026, 20:54 UTC

Ganhos

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12 de jan. de 2026, 20:48 UTC

Conversa de Mercado

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12 de jan. de 2026, 20:33 UTC

Conversa de Mercado

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12 de jan. de 2026, 20:18 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12 de jan. de 2026, 20:18 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12 de jan. de 2026, 19:39 UTC

Conversa de Mercado

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12 de jan. de 2026, 19:36 UTC

Conversa de Mercado

Gold and Silver Set New Records on Fed Probe -- Market Talk

12 de jan. de 2026, 19:36 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

12 de jan. de 2026, 19:33 UTC

Conversa de Mercado

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12 de jan. de 2026, 19:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12 de jan. de 2026, 19:22 UTC

Aquisições, Fusões, Aquisições de Empresas

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12 de jan. de 2026, 18:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12 de jan. de 2026, 18:20 UTC

Aquisições, Fusões, Aquisições de Empresas

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12 de jan. de 2026, 18:19 UTC

Conversa de Mercado

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12 de jan. de 2026, 18:16 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12 de jan. de 2026, 18:09 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

12 de jan. de 2026, 18:09 UTC

Conversa de Mercado

Baidu's Outlook Bodes Well For Shares -- Market Talk

12 de jan. de 2026, 18:01 UTC

Aquisições, Fusões, Aquisições de Empresas

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12 de jan. de 2026, 18:00 UTC

Conversa de Mercado

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Comparação entre Pares

Variação de preço

ResMed Inc Previsão

Preço-alvo

By TipRanks

14.02% parte superior

Previsão para 12 meses

Média 294 USD  14.02%

Máximo 345 USD

Mínimo 260 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para ResMed Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

6

Comprar

5

Manter

0

Vender

Sentimento

By Acuity

109 / 370 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre ResMed Inc

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
help-icon Live chat